No Data
No Data
Actinogen Medical Expects Results From XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%
Actinogen Medical (ASX:ACW) expects to report by early next month the results of a phase 2a clinical trial of XanaCIDD in patients with cognitive impairment in major depressive disorder, according to
Actinogen's Xanamem Could Slow Alzheimer's Progress, New Biomarker Trial Reveals
A biomarker trial of Actinogen Medical’s (ASX: ACW) lead candidate Xanamem has been published in the peer-reviewed Journal of Alzheimer’s Disease, with results showing the drug has the potential to slow disease progression in patients with elevated levels of phosphorylated tau (pTau).
Stocks of the Hour: Actinogen Medical, De Grey Mining, Cooper Metals
Actinogen Medical (ASX:ACW) announced positive results from the Xanamem phase 2a biomarker trial in patients with elevated blood pTau. In response, Dr Dana Hilt, the Company's Chief Medical Officer sa
Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer
Actinogen Medical (ASX:ACW) raised up to AU$3.9 million through the completion of its oversubscribed non-renounceable one-for-15 entitlement offer, according to a Thursday filing with the Australian b
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%
Actinogen Medical (ASX:ACW) on Wednesday opened its AU$3.9 million 1-for-15 entitlement offer priced at AU$0.025 per share. Proceeds will be used to advance the XanaMIA trial in patients with mild to
Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer
Actinogen Medical (ASX:ACW) lodged the prospectus for a 1-for-15 entitlement offer priced at AU$0.025 per share to raise up to AU$3.9 million. The shares come with 1-for-2 options that expire May 31,
No Data